Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | ADORA2A | P29274 | 1/20 | 0.58 |
| ▸ | ADORA1 | P30542 | 1/20 | 0.58 |
| ▸ | NUDT1 | P36639 | 2/20 | 0.57 |
| ▸ | PI4KA | P42356 | 8/20 | 0.50 |
| ▸ | PI4K2B | Q8TCG2 | 8/20 | 0.50 |
| ▸ | PI4K2A | Q9BTU6 | 8/20 | 0.50 |
| ▸ | PI4KB | Q9UBF8 | 8/20 | 0.50 |
| ▸ | LMNA | P02545 | 3/20 | 0.45 |
| ▸ | TSHR | P16473 | 1/20 | 0.45 |
| ▸ | DRD3 | P35462 | 1/20 | 0.44 |
| ▸ | XDH | P47989 | 1/20 | 0.44 |
| ▸ | LRRK2 | Q5S007 | 1/20 | 0.44 |
| ▸ | ERBB2 | P04626 | 1/20 | 0.43 |
| ▸ | HSP90AA1 | P07900 | 1/20 | 0.43 |
| ▸ | HSP90AB1 | P08238 | 1/20 | 0.43 |
| ▸ | PKM | P14618 | 1/20 | 0.43 |
| ▸ | APEX1 | P27695 | 1/20 | 0.42 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.42 |
| ▸ | NPSR1 | Q6W5P4 | 1/20 | 0.42 |
| ▸ | KDM4E | B2RXH2 | 1/20 | 0.42 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL42314 | 0.80 | ADORA2A (0.66) | ADORA2AADORA1NUDT1PI4KAPI4K2B | |
| SCHEMBL29400753 | 0.80 | ADORA2A (0.66) | ADORA2AADORA1NUDT1PI4KAPI4K2B | |
| SCHEMBL30109321 | 0.79 | NUDT1 (0.68) | ADORA2AADORA1NUDT1PI4KAPI4K2B | |
| SCHEMBL1059581 | 0.79 | NUDT1 (0.68) | ADORA2AADORA1NUDT1PI4KAPI4K2B | |
| SCHEMBL887193 | 0.78 | MAP4K4 (0.39) | ADORA2AADORA1NUDT1PI4KAPI4K2B | |
| SCHEMBL8566 | 0.73 | ADORA2A (1.00) | ADORA2AADORA1NUDT1PI4KAPI4K2B | |
| SCHEMBL843169 | 0.73 | ADORA2A (0.61) | ADORA2AADORA1NUDT1PI4KAPI4K2B | |
| SCHEMBL1251786 | 0.73 | — | — | |
| SCHEMBL842440 | 0.73 | ADORA2A (0.61) | ADORA2AADORA1NUDT1PI4KAPI4K2B | |
| SCHEMBL42335 | 0.73 | ADORA2A (0.61) | ADORA2AADORA1NUDT1PI4KAPI4K2B |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 51 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-9725474-B2 | Modified nucleic acid | TAKEDA PHARMACEUTICAL COMPANY LIMITED (JP) | 2017-08-08 | — | — | US | claimed |
| US-5665541-A | Formation of triple helix complexes for the detection of double stranded DNA sequences using oligomers which comprise an 8-modified purine base | THE JOHNS HOPKINS UNIVERSITY (US) | 1997-09-09 | — | — | US | claimed |
| EP-0672171-A1 | FORMATION OF TRIPLE HELIX COMPLEXES OF DOUBLE STRANDED DNA USING NUCLEOSIDE OLIGOMERS WHICH COMPRISE PURINE BASE ANALOGS | THE JOHNS HOPKINS UNIVERSITY (US) | 1995-09-20 | — | — | EP | claimed |
| WO-1993005180-A1 | FORMATION OF TRIPLE HELIX COMPLEXES OF DOUBLE STRANDED DNA USING NUCLEOSIDE OLIGOMERS WHICH COMPRISE PURINE BASE ANALOGS | THE JOHNS HOPKINS UNIVERSITY (US) | 1993-03-18 | — | — | WO | claimed |
| US-10391166-B2 | Short oligonucleotides as vaccine adjuvants and therapeutic agents | SPRING BREAK PHARMACEUTICALS, INC. (US) | 2019-08-27 | — | — | US | disclosed |
| EP-2915815-B1 | NEW MODIFIED NUCLEIC ACID | TAKEDA PHARMACEUTICALS CO (JP) | 2018-01-17 | — | — | EP | disclosed |
| US-9725474-B2 | Modified nucleic acid | TAKEDA PHARMACEUTICAL COMPANY LIMITED (JP) | 2017-08-08 | — | — | US | disclosed |
| CN-105992587-A | Design of short oligonucleotides as vaccine adjuvants and therapeutic agents | 春堤制药公司 | 2016-10-05 | — | — | CN | disclosed |
| US-20160016983-A1 | New Modified Nucleic Acid | TAKEDA PHARMACEUTICAL COMPANY LIMITED (JP) | 2016-01-21 | — | — | US | disclosed |
| US-20150374816-A1 | DESIGN OF SHORT OLIGONUCLEOTIDES AS VACCINE ADJUVANTS AND THERAPEUTIC AGENTS | SPRING BANK PHARMACEUTICALS, INC. | 2015-12-31 | — | — | US | disclosed |
| EP-2956145-A2 | DESIGN OF SHORT OLIGONUCLEOTIDES AS VACCINE ADJUVANTS AND THERAPEUTIC AGENTS | Spring Bank Pharmaceuticals, Inc. (US) | 2015-12-23 | — | — | EP | disclosed |
| EP-2915815-A1 | NEW MODIFIED NUCLEIC ACID | Takeda Pharmaceutical Company Limited (JP) | 2015-09-09 | — | — | EP | disclosed |
| US-5968745-A | ELECTRODE OF SUBSTRATE HAVING ELECTROCONDUCTIVE WORKING SURFACE AND A NONCONDUCTIVE OUTER POLYMER LAYER WHERE PROBES CAN BE ATTACHED HAVING MICROFLUIDIC REACTION OPENINGS FOR TRANSITION METAL COMPLEX TO TRANSFER ELECTRONS TO SURFACE | THE UNIVERSITY OF NORTH CAROLINA AT CHAPEL HILL (US) | 1999-10-19 | — | — | US | disclosed |
| US-5871918-A | DNA AND RNA HYBRIDIZATION DETECTION BY REACTION WITH TRANSITION METAL COMPLEX FOR OXIDATION-REDUCTION REACTION | THE UNIVERSITY OF NORTH CAROLINA AT CHAPEL HILL (US) | 1999-02-16 | — | — | US | disclosed |
| EP-0871773-A2 | ELECTROCHEMICAL DETECTION OF NUCLEIC ACID HYBRIDIZATION | UNIVERSITY OF NORTH CAROLINA AT CHAPEL HILL (US) | 1998-10-21 | — | — | EP | disclosed |
| CN-1192249-A | Electrochemical detection of nucleic acid hybridization | UNIV NORTH CAROLINA (US) | 1998-09-02 | — | — | CN | disclosed |
| US-5665541-A | Formation of triple helix complexes for the detection of double stranded DNA sequences using oligomers which comprise an 8-modified purine base | THE JOHNS HOPKINS UNIVERSITY (US) | 1997-09-09 | — | — | US | disclosed |
| WO-1997001646-A2 | ELECTROCHEMICAL DETECTION OF NUCLEIC ACID HYBRIDIZATION | THE UNIVERSITY OF NORTH CAROLINA AT CHAPEL HILL (US) | 1997-01-16 | — | — | WO | disclosed |
| EP-0672171-A1 | FORMATION OF TRIPLE HELIX COMPLEXES OF DOUBLE STRANDED DNA USING NUCLEOSIDE OLIGOMERS WHICH COMPRISE PURINE BASE ANALOGS | THE JOHNS HOPKINS UNIVERSITY (US) | 1995-09-20 | — | — | EP | disclosed |
| WO-1993005180-A1 | FORMATION OF TRIPLE HELIX COMPLEXES OF DOUBLE STRANDED DNA USING NUCLEOSIDE OLIGOMERS WHICH COMPRISE PURINE BASE ANALOGS | THE JOHNS HOPKINS UNIVERSITY (US) | 1993-03-18 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (3 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20150374816-A1 | DESIGN OF SHORT OLIGONUCLEOTIDES AS VACCINE ADJUVANTS AND THERAPEUTIC AGENTS | TLR3, TLR5, TLR9 | ADORA2A 303/4885ADORA1 35/4885NUDT1 60/4885 |
| US-20160016983-A1 | New Modified Nucleic Acid | RNGTT, RNASEH1, RNASE1 | ADORA2A 299/4885ADORA1 360/4885NUDT1 202/4885 |
| US-10391166-B2 | Short oligonucleotides as vaccine adjuvants and therapeutic agents | TLR3, TLR5, TLR9 | ADORA2A 292/4885ADORA1 44/4885NUDT1 67/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.